Recent Updates
Recently added Catalysts
ICU Positive Sentiment Score: 70/100

SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

Wednesday, November 5, 2025 2 min read
Key Takeaway: SeaStar Medical Holding Corporation will announce its third quarter financial results on November 13, 2025. The company focuses on innovative treatments for critically ill patients, particularly those facing organ failure. Its QUELIMMUNE therapy, approved by the FDA, addresses life-threatening acute kidney injury in pediatric patients. Additionally, SeaStar is conducting pivotal trials for adult AKI patients.

Market Sentiment Analysis

POSITIVE FACTORS

  • SeaStar Medical is set to report its third quarter financial results.
  • The QUELIMMUNE therapy is the only FDA approved treatment for a rare condition.
  • The company has received Breakthrough Device Designation for multiple indications.
  • Ongoing pivotal trials may lead to new treatment options for AKI patients.

Full Press Release Details

DENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Thursday, November 13, 2025, and host a webcast and conference call to discuss its financial results and business progress.
Date/Time: Thursday, November 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MT
Webcast: The live webcast and replay can be foundhere.
Dial-in number: To join the conference call via phone, please pre-register onlinehereto receive a telephone number and unique passcode required to enter the call.
A replay of the webcast will be available after 7:30 pm ET and can be accessedhere.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. TheQUELIMMUNE (SCD-PED)therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visitwww.seastarmedical.comor visit us onLinkedInorX.

Contact:SeaStar Investor Relations:IR@SeaStarMed.com

Frequently Asked Questions

When will SeaStar Medical report its Q3 financial results?

SeaStar Medical will report its third quarter financial results on November 13, 2025.

What is QUELIMMUNE therapy?

QUELIMMUNE therapy is SeaStar Medical's FDA-approved treatment for life-threatening acute kidney injury.

What designation has SeaStar Medical received from the FDA?

SeaStar Medical's Selective Cytopheretic Device therapy has received Breakthrough Device Designation for six indications.

What condition does SeaStar's therapy target?

The therapy targets acute kidney injury due to sepsis in critically ill pediatric patients.

What trial is SeaStar currently conducting?

SeaStar is conducting a pivotal trial of its SCD therapy in adult patients with AKI.

Tags: ICU Viatris Investor Conferences Healthcare SeaStar Medical QUELIMMUNE FDA approval acute kidney injury
Last updated: Nov 5, 2025